Navigation Links
Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
Date:8/19/2008

on (DKK 448 million). The Company has released trusted funds of DKK 80 million to improve the net free liquidity. Furthermore, there are unused credit facilities of DKK 20 million.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology MVA-BN(R) is one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the U.S. government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com

"Safe Harbour" Statement Under the Private Securities Litigation Reform Act of 1995:

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. No "forward-looking statement" can be guaranteed, and actual results may differ materially from those projected. Bavarian Nordic undertakes no obligation to publicly update any "forward-looking statement", whether as a result of new information, future events, or otherwise. Additional information regarding risks and uncertainties is set forth in the current Annual Report, which we incorporate by reference.


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
2. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
3. LPBP Inc. - Re-filing certification of interim filings
4. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
7. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
8. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
9. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
10. Steve Davis Joins Infectious Disease Research Institute (IDRI) as Interim CEO
11. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...re/ -- The world,s first concept demonstration t...ugh alternative to replace a petrochemically produ...ber with renewable biomass, made their debut in Co...display at a lounge in the common departure area a...December 21, while the other tire will make appear...
(Date:12/2/2009)...swire-FirstCall/ - Oncolytics Biotech Inc. ("Oncol...announced today that in connection with its previo...e exercised in full their over-allotment option an... is comprised of one common share and 0.4 of a com...e of US$3.00 per unit. Each whole common share pur...
(Date:12/2/2009)...s, December 2 Pepscan Holding NV,...ng on protein mimicking,technology for the generat...,has appointed Wim E.M. Mol, Ph.D. as new Chief Ex...sible for all of Pepscans corporate functions and,...the company. He brings to,Pepscan more than 20 yea...
(Date:12/2/2009)... December 2 Gamida Cell announced ...al (animal study) safety and,efficacy of a gene th...,Cornell Medical College and Gamida Cell. The prod...such as Cooley,s Anemia. , Gamida Cell is... vivo,populations of stem/progenitor cells. The c...
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Dutch Biotech Company Pepscan Appoints New CEO 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3
...today,announced the appointment of industry vetera... further bolstering its position as a leader in th...Mr. Bailye, 54, recently retired from his position... Dendrite was acquired by French information,provi...te, a pharmaceutical,sales force automation system...
...HERAL VASCULAR DEVICE MARKET INSIGHTS WEBINAR ... Thursday, June 5, 2008, 11 am US Eastern Ti...s), PRESENTER: Stephanie LaBelle, Analyst from ...e the link below to register or call Shiu-Yik Au a...Research Group presents a complimentary Webinar ou...
...ire-FirstCall/ - Quest PharmaTech Inc. (TSX-V:,QPT...t its 12-patient,Phase I clinical study entitled "...todynamic Therapy of Actinic Keratosis" has met bo...re delighted to have received, for the first time,...in a dermatological application,",said Madi R. Mad...
Other Biology Technology:IntegriChain Appoints John Bailye to Its Board of Directors 2Peripheral Vascular Device Market Insights Webinar 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 3
(Date:12/3/2009)... investment in energy efficient technologies resea...h Council (EPSRC) Chief Executive Dave Delpy belie...ng research has already brought us fuel cells, mar...stment is needed to develop the capabilities of di...ssion targets by 2020 and limit the impact of clim...
(Date:12/2/2009)...ino men have a more difficult time quitting smokin...ture, but acculturation has no affect on Latinas o... are published in Cancer Epidemiology, Biomarkers...ion for Cancer Research. The December issue has a ...ts smoking cessation differently for Latino men an...
(Date:12/2/2009)...cents exposed to cigarette smoking scenes in movie... and this may be part of the acculturation process...new study findings. , "Our study supports an R-r...hts the global implementation of the World Health ...ol, which includes guidelines for countries to res...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Acculturation affects smoking cessation success among Latinos 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hema 6741 1Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hema 6741 2Blood Clot Threat After Surgery Worse Than Thought 62571 1Blood Clot Threat After Surgery Worse Than Thought 62571 2Blood Clot Threat After Surgery Worse Than Thought 62571 3Blood Sugar Intolerance May Predict Postpartum Ills 62567 1Blood Sugar Intolerance May Predict Postpartum Ills 62567 2
...TON, DC -- Sweetpotatoes, often misunderstood and ...saving food crop in developing countries. , Accor...tato.org ), more than 95 percent of the global swe...ere it is the fifth most important food crop. Desp...e potato. Potatoes are tubers (referring to their ...
...ts have identified a new way to breed brassicas, w...esistant to a damaging virus. Their discovery has ... be durable, broad-spectrum and unlikely to be ove...(TuMV) is an economically devastating virus that i...cially brassicas. In research published recently i...
...ama Barkai will receive the Helen and Martin Kimme...v. 5 at the Weizmann Institute. The award is accom...er five years. , Taking a chance on an experiment.... Living cells are, from this angle, great subject... have all sorts of interesting consequences for ma...
Other Biology News:Sweet potato shines as new promise for small enterprise and hunger relief in developing countries 2Sweet potato shines as new promise for small enterprise and hunger relief in developing countries 3Genes identified to protect brassicas from damaging disease 2Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2
Biolase Core Kit from Bioline
...amplification of GC-rich nucleic acids ,The GC-... a proofreading polymerase, powers through templat...h other polymerases and other blends of polymerase...unique GC-RICH Resolution Solution combine to deli...
...nogen: synthetic peptide corresponding to the thir..., conjugated to KLH. The immunizing peptide has 79...form: Solution in phosphate buffered saline, pH 7....d: IHC (p). Titertest values: immunohistochemistr...
CnC (Cn402-05) from European Collection of Cell Cultures (ECACC)
Biology Products: